A small portion of Gilead’s 11% increase in revenue for the second quarter of 2011 compared to the same quarter in 2010 is attributable to a 105% increase in the US sales of Cayston astreonam inhalation solution over that period. The company’s revenues for the quarter totaled $2.14 billion. Sales of Cayston for the treatment of P. aeruginosa infections in cystic fibrosis patients rose from $10.5 million in the second quarter of 2010 to $21.5 million in the second quarter of 2011.
The US FDA approved Cayston in February 2010, and the European Union and Canada granted conditional marketing authorization in 2009. A drug-specific Altera nebulizer system from PARI is used to deliver the inhalation solution.
Read the Gilead press release.
